← Leaderboards
Paul Thomas Henderson
Massachusetts Institute Of Technology
$3,910,692
Attributed
$4,692,641
Total exposure
17
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $516.9K · FY2005–19$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$4,692,641 · 17
By mechanism
P41$1,743,687 · 10
R01$1,563,899 · 1
R43$824,999 · 3
R44$291,894 · 1
N43$195,550 · 1
F32$72,612 · 1
Top collaborators
- Matthew Adrian Coleman5 shared
Most similar at Massachusetts Institute Of Technology
Same institution · by research overlap
- John Lamar$842,526
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsCellsLeadPharmaceutical PreparationsProteinsTumorTissuesAnimalsFundingDosePropertyInstitutionBaseGrantTechnologyDesignComputer Retrieval Of Information On Scientific Projects DatabaseResourcesCancer PatientCarcinogenesisNew TechnologyResearch PersonnelSourceUnited States National Institutes Of Health
Grant awards (22)
Bladder cancer chemotherapy potentiation with a multiprong arachidonic acid pathway modulator$300,000
R43 · FY2019 · CA · contact PI
Extremely long tumor retention, on-demand releasing Nano-Taxel for eradicating ovarian cancers$291,894
R44 · FY2018 · CA · contact PI
Ninja Theranostics for overcoming the drug delivery barriers to pediatric brain tumor$225,000
R43 · FY2018 · HD · contact PI
Feasibility of predicting AML response to induction chemotherapy$299,999
R43 · FY2017 · CA · contact PI
Characterization of Erbb Receptors in Nanoparticles$318,513
R01 · FY2015 · CA · contact PI
Characterization of Erbb Receptors in Nanoparticles$308,958
R01 · FY2014 · CA · contact PI
Characterization of Erbb Receptors in Nanoparticles$299,402
R01 · FY2013 · CA · contact PI
Characterization of Erbb Receptors in Nanoparticles$318,513
R01 · FY2012 · CA · contact PI
Characterization of Erbb Receptors in Nanoparticles$318,513
R01 · FY2011 · CA · contact PI
Phase 0 carboplatin microdosing diagnostics trial$195,550
N43 · FY2010 · CA · contact PI
DEVELOP ASSAY TO QUANT PLAT-DNA ADDUCTS & PREDICT RESPONSE TO CHEMOTHERA$169,921
P41 · FY2010 · RR · contact PI
PROJECT 3 : QUANTITATIVE BIOMARKERS OF DNA AND PROTEIN OXIDATION$319,907
P41 · FY2009 · RR · contact PI
OXIDIZED DNA BASES AS BIOMARKERS OF TUMOR PROGRESSION$68,313
P41 · FY2009 · RR · contact PI
PROJECT 3 : QUANTITATIVE BIOMARKERS OF DNA AND PROTEIN OXIDATION$298,136
P41 · FY2008 · RR · contact PI
OXIDIZED DNA BASES AS BIOMARKERS OF TUMOR PROGRESSION$63,664
P41 · FY2008 · RR · contact PI
PROJECT 3 : QUANTITATIVE BIOMARKERS OF DNA AND PROTEIN OXIDATION$273,421
P41 · FY2007 · RR · contact PI
OXIDIZED DNA BASES AS BIOMARKERS OF TUMOR PROGRESSION$40,562
P41 · FY2007 · RR · contact PI
PROJECT 3 : QUANTITATIVE BIOMARKERS OF DNA AND PROTEIN OXIDATION$276,195
P41 · FY2006 · RR · contact PI
OXIDIZED DNA BASES AS BIOMARKERS OF TUMOR PROGRESSION$86,678
P41 · FY2006 · RR · contact PI
OXIDIZED DNA BASES AS BIOMARKERS OF TUMOR PROGRESSION$146,890
P41 · FY2005 · RR
FLANKING BASE SEQUENCE ON MUTAGENICITY OF 8 OXOGUANINE$40,196
F32 · FY2001 · CA
FLANKING BASE SEQUENCE ON MUTAGENICITY OF 8 OXOGUANINE$32,416
F32 · FY2000 · CA